Zobrazeno 31 - 40
of 288
pro vyhledávání: ''
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 260 (2011)
BMC Cancer, Vol 11, Iss 1, p 260 (2011)
Background Our objective was to measure myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) risk associated with radiation and/or chemotherapy breast cancer (BC) treatment. Methods Our study cohort was composed of BC patients diagnose
Autor:
Riikka Nurminen, Johanna Schleutker, Heli Nevanlinna, Liisa M. Pelttari, Lauri A. Aaltonen, Alexandra E. Gylfe
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 552 (2012)
BMC Cancer
BMC Cancer
Background Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not
Autor:
Barbara Perić, Radan Dzodic, Rok Petric, Gasper Pilko, Hana Besic, Jan Zmuc, Nikola Besic, Andraz Perhavec
Publikováno v:
BMC Cancer
Background The population of elderly people is increasing and so is the population of breast cancer patients aged ≥80 years. The aim of our retrospective study was to identify independent prognostic factors for the duration of breast cancer-specifi
Autor:
Sandra Salvi, Pier Vitale Nuzzo, L. Zinoli, Francesco Boccardo, Simona Boccardo, Alessandra Rubagotti
Publikováno v:
BMC Cancer
Background PN is a secreted cell adhesion protein critical for carcinogenesis. In breast cancer, it is overexpressed compared to normal breast, and a few reports suggest that it has a potential role as a prognostic marker. Methods Tumour samples obta
Publikováno v:
BMC Cancer
© 2017 The Author(s). Background: Breast cancer is the most frequently diagnosed cancer in women. Resident macrophages at distant sites provide a highly responsive and immunologically dynamic innate immune response against foreign infiltrates. Despi
Autor:
Yvonne Nestoriuc, Franziska Schuricht, Ute-Susann Albert, Winfried Rief, Pia von Blanckenburg
Publikováno v:
BMC Cancer
Background Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients’ quality of life and cause non-ad
Publikováno v:
BMC Cancer
Background Breast cancer is one of the most deadly diseases in women. Inhibiting the synthesis of estrogen is effective in treating patients with estrogen-responsive breast cancer. Previous studies have demonstrated that use of cyclooxygenase (COX) i
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 228 (2010)
BMC Cancer
BMC Cancer
Background The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recogni
Autor:
Gina Bouchard, Yves Bérubé-Lauzière, Hélène Therriault, Sameh Geha, Rachel Bujold, Caroline Saucier, Benoit Paquette
Publikováno v:
BMC Cancer
Background Some triple negative breast cancer (TNBC) patients are at higher risk of recurrence in the first three years after treatment. This rapid relapse has been suggested to be associated with inflammatory mediators induced by radiation in health
Autor:
Karin Jirström, Donal J. Brennan, William M. Gallagher, Elton Rexhepaj, Michael J. Duffy, Darran P. O'Connor, Sallyann L. O'Brien, Göran Landberg
Publikováno v:
BMC Cancer
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
Background Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indicator in breast cancer. Here, w